Peimine, derived from the Fritillaria genus, has long been recognized for its anti- inflammatory properties. In the present study, we investigated the potential of peimine as an antipruritic and anti-inflammatory agent using a combination of in vitro,...
Peimine, derived from the Fritillaria genus, has long been recognized for its anti- inflammatory properties. In the present study, we investigated the potential of peimine as an antipruritic and anti-inflammatory agent using a combination of in vitro, ex vivo, and in vivo experimental approaches. In vitro calcium imaging assays demonstrated that peimine inhibited key pruritus related receptors, including TRPM3, MRGPRX2, and MRGPRB2, while exerting minimal or no effects on TRPA1, TRPV1, and TRPV4. These findings indicate a degree of selectivity toward itch-related signaling pathways. Ex vivo experiments using dorsal root ganglion neurons further confirmed that peimine significantly suppressed TRPM3 mediated calcium responses. In addition, β-hexosaminidase release assays showed that peimine inhibited MRGPRB2 mediated degranulation in peritoneal mast cells and MRGPRX2 mediated degranulation in human mast cells HMC 1.2. Consistent with these cellular effects, in vivo models of acute itch revealed that peimine markedly reduced scratching behavior induced by pregnenolone sulfate, a TRPM3 agonist, as well as compound 48/80, an MRGPRB2 agonist. Furthermore, peimine attenuated inflammatory swelling in a compound 48/80 induced paw edema model, supporting its anti-inflammatory activity. Collectively, these results identify peimine as a promising therapeutic candidate for the management of pruritus. Key words: Peimine, pruritus, calcium imaging, TRP, MRGPRX2, MrgprB2, compound 48/80, mast cells, itch